| Methods |
RCT.
Double‐masked.
Active controlled. |
| Participants |
51 participants with OAG or OHT (1 patient).
Racial constitution is not reported.
Inclusion criteria: IOP 23 mmHg or higher.
Exclusion criteria: secondary glaucoma, angle closure glaucoma, c/d ratio of more than 0.7 in either eye, aphakia, chronic ocular inflammation, systemic beta‐blockers. |
| Interventions |
Timolol 0.5% twice daily.
Levobunolol 0.5% twice daily.
Levobunolol 1% twice daily. |
| Outcomes |
IOP control.
Cup/disc‐ratio (direct ophthalmoscopy).
Incidence of glaucomatous visual field defect (Goldmann). |
| Notes |
Allocation concealment deemed likely, based on double‐masked design.
4 years follow up.
14 drop‐outs: 6 levobunolol 0.5% (3 drug‐related adverse events), 6 levobunolol 1% (1 drug‐related adverse effect), 2 timolol (not drug‐related). Between 41% and 53% of the participants terminated their participation due to inadequate IOP control, resulting in successful completion of the study by only 23%‐24% and 35% of patients in the 3 groups. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
